Therapeutic effect of moxifloxacin nebulized inhalation on chronic obstructive pulmonary disease with type II respiratory failure and the effect on related clinical indicators

Jia Xiaojia

doi:10.3760/j.issn.1673-4777.2019.07.007

Abstract：Objective To analyze the therapeutic effect of moxifloxacin nebulized inhalation on chronic obstructive pulmonary disease(COPD) with type Ⅱ respiratory failure and its effect on related clinical indicators.Methods Eighty-two COPD patients with type Ⅱ respiratory failure admitted to Beijing Hepingli Hospital from April 2015 to July 2016 were randomly divided into control group and moxifloxacin group,with 41 cases in each group.The control group had routine anti-infective therapy;the moxifloxacin group was treated with nebulized inhalation of moxifloxacin solution on the basis of routine therapy.Serum inflammatory factors,arterial blood gas indexes,creatine kinase,aspartate aminotransferase and Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) were analyzed before and after treatment.Therapeutic efficacy and adverse reactions were analyzed.Results The total effective rate in moxifloxacin group was significantly higher than that in control group [95.1％ (39/41) vs 78.0％ (32/41)] (P ＜ 0.05).After treatment,levels of serum tumor necrosis factor-α,C-reactive protein,arterial partial pressure of carbon dioxide,creatine kinase,aspartate aminotransferase and APACHE Ⅱ score significantly decreased in both groups;the indexes in moxifloxacin group were significantly lower than those in control group(all P ＜ 0.05).Serum level of interleukin-10 and arterial partial pressure of oxygen significantly increased in both groups and they were significantly higher in moxifloxacin group than those in control group(all P ＜ 0.05).Conclusion Nebulized inhalation of moxifloxacin solution treating COPD with type Ⅱ respiratory failure can effectively improve arterial blood gas,reduce inflammatory response,reduce myocardial cell damage and improve patients' physiological condition with good safety.